,26,29 Our research in the three cohorts confirmed that the presence of CXCL13+ T cells is a strong determinant of ICB response and could be served as potential targets for improving ICB response, not only in the first reported CRC multiomics dataset but also in a broader pan-cancer context. The gene discussed is CXCL13; the disease is cancer.